Coartem Baby, developed through collaboration between Medicines for Malaria Venture and Novartis, has received approval for use in newborns and infants weighing less than 11 pounds. This malaria drug is significant in addressing treatment gaps for the most vulnerable victims of the disease, particularly children under five years old. Malaria remains a global health threat, with millions of cases and deaths reported annually. The drug is designed to be dissolvable in breast milk and has a palatable sweet cherry flavor for easier administration.
Coartem Baby, developed by Medicines for Malaria Venture and Novartis, is the first malaria drug approved for infants and those weighing under 11 pounds.
Despite being preventable and treatable, malaria continues to pose a significant health threat, with 263 million cases and 597,000 deaths reported globally in 2023.
Children under 5 account for approximately 76 percent of all malaria deaths in the WHO's Africa region, according to 2023 figures.
The newly authorized product, Coartem Baby, addresses a critical gap in treatment options for vulnerable infants suffering from malaria.
Collection
[
|
...
]